May 2006
Volume 47, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2006
Results ff Optical Coherence Tomography During Pegaptanib (Macugen) Therapy For Neovascular Age–Related Macular Degeneration
G.G. Emerson; S. Nolte; D.J. Wilson; J.T. Stout; C.J. Flaxel; A.K. Lauer; M.L. Klein
Author Affiliations & Notes
  • G.G. Emerson
    Ophthalmology, Casey Eye Institute, Portland, OR
  • S. Nolte
    Ophthalmology, Casey Eye Institute, Portland, OR
  • D.J. Wilson
    Ophthalmology, Casey Eye Institute, Portland, OR
  • J.T. Stout
    Ophthalmology, Casey Eye Institute, Portland, OR
  • C.J. Flaxel
    Ophthalmology, Casey Eye Institute, Portland, OR
  • A.K. Lauer
    Ophthalmology, Casey Eye Institute, Portland, OR
  • M.L. Klein
    Ophthalmology, Casey Eye Institute, Portland, OR
  • Footnotes
    Commercial Relationships  G.G. Emerson, None; S. Nolte, None; D.J. Wilson, None; J.T. Stout, None; C.J. Flaxel, None; A.K. Lauer, None; M.L. Klein, None.
  • Footnotes
    Support  Research to Prevent Blindness
Investigative Ophthalmology & Visual Science May 2006, Vol.47, 5242. doi:
  • Views
  • Share
  • Tools
    • Alerts
      User Alerts
      You are adding an alert for:
      Results ff Optical Coherence Tomography During Pegaptanib (Macugen) Therapy For Neovascular Age–Related Macular Degeneration
      You will receive an email whenever this article is corrected, updated, or cited in the literature. You can manage this and all other alerts in My Account
      The alert will be sent to:
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation
      Citation

      G.G. Emerson, S. Nolte, D.J. Wilson, J.T. Stout, C.J. Flaxel, A.K. Lauer, M.L. Klein; Results ff Optical Coherence Tomography During Pegaptanib (Macugen) Therapy For Neovascular Age–Related Macular Degeneration . Invest. Ophthalmol. Vis. Sci. 2006;47(13):5242.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

      ×
    • Get Permissions
  • Supplements
Abstract

Purpose: : To evaluate macular thickness measured by optical coherence tomography (OCT) during pegaptanib therapy for neovascular age–related macular degeneration (AMD).

Methods: : Intravitreous pegaptanib (1 mg) injections were repeated every 6 weeks (n = 40 eyes from 40 patients). The primary outcome measure was central macular thickness measured by OCT. Secondary outcomes were fluorescein angiographic leakage and visual acuity.

Results: : Thickness of the central area on OCT decreased from 340 ± 24 µm to 280 ± 20 µm (P = 0.02) over the first 24 weeks of pegaptanib injections. During the same time period, fluorescein angiograms with definite leakage decreased from 100% to 54%, and visual acuity was stable (20/117 vs. 20/127; P = 0.7).

Conclusions: : Central macular thickness secondary to neovascular AMD responds modestly to intravitreal injections of pegaptanib at 6–week intervals.

Keywords: age-related macular degeneration • choroid: neovascularization 
© 2006, The Association for Research in Vision and Ophthalmology, Inc., all rights reserved. Permission to republish any abstract or part of an abstract in any form must be obtained in writing from the ARVO Office prior to publication.
Copyright © 2024 Association for Research in Vision and Ophthalmology.
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×
This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.Accept